Docoh
Loading...

BBIO BridgeBio Pharma

News

From Benzinga Pro
BridgeBio Pharma, Helsinn Report Strategic Collab To Co Develop, Co Commercialize BridgeBio's Novel GPX4 Inhibitor Cancer Tumor Types
19 Nov 21
Biotech, News, FDA, General
- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs - BridgeBio and Helsinn have
SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $66
19 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $68 to $66.
BridgeBio Pharma Secures Debt Financing Of $750M
18 Nov 21
Biotech, News, Health Care, Financing, Offerings, General
BridgeBio Pharma Reports Secured Up To $750M In Non-Dilutive Debt Financing
18 Nov 21
News, Bonds, Financing, Markets
-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company’s 30+ genetic disease and cancer pipeline programs into 2024 PALO
BridgeBio Pharma Q3 EPS $(1.06) Down From $(0.98) YoY, Sales $2.34M Down From $8.13M YoY
4 Nov 21
Earnings, News
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(1.06) per share. This is a 8.16 percent decrease over losses of $(0.98) per share from the same period last year. The company reported $2.34 million in sales
BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy For Canavan Disease
3 Nov 21
Biotech, News, FDA, General
BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in CANaspire, its Phase 1/2
BridgeBio Pharma Reports Collabs With Columbia University, Mount Sinai To Develop Potential Therapies For Genetic Diseases, Cancers
29 Oct 21
Biotech, News, FDA, General
- The new agreements mean BridgeBio has collaborations with 25 leading academic institutions focused on genetic disease and precision oncology PALO ALTO, Calif., Oct. 29, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc.
HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $88
25 Oct 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $87 to $88.
BridgeBio Pharma Announces First Publication Of Preclinical Data For Potentially Best-In-Class SHP2 Inhibitor Designed For Treatment Of Resistant Cancer, Showing Response In Established Non-small Cell Lung Cancer Models
7 Oct 21
News, FDA
BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced preclinical findings for its SHP2 inhibitor, BBP-398, in
10 Biggest Price Target Changes For Monday
4 Oct 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
RBC Capital boosted Tesla, Inc. (NASDAQ: TSLA) price target from $745 to $755. Tesla shares rose 2.9% to $797.67 in pre-market trading.
SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $68
4 Oct 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $66 to $68.
BridgeBio Pharma's Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US
15 Sep 21
Biotech, News, Health Care, FDA, Movers, Trading Ideas, General
BridgeBio Pharma Receives FDA Fast Track Designation For Investigational Therapy For The Treatment Of Limb-girdle Muscular Dystrophy Type 2i
15 Sep 21
News, FDA
BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic
B of A Securities Upgrades BridgeBio Pharma to Buy, Announces $75 Price Target
10 Sep 21
News, Upgrades, Price Target, Analyst Ratings
B of A Securities analyst Geoff Meacham upgrades BridgeBio Pharma (NASDAQ:BBIO) from Neutral to Buy and announces $75 price target.

Press releases

From Benzinga Pro
BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio's Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
19 Nov 21
Health Care, Press Releases
- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs - BridgeBio and Helsinn have
BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
18 Nov 21
News, Financing, Press Releases
-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company's 30+ genetic disease and cancer pipeline programs into 2024 PALO ALTO,
BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update
4 Nov 21
Earnings, Press Releases
PALO ALTO, Calif., Nov. 4, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
3 Nov 21
Press Releases
PALO ALTO, Calif., Nov. 3, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
29 Oct 21
Press Releases
PALO ALTO, Calif., Oct. 29, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced two new academic collaborations
BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors
25 Oct 21
Press Releases
PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new
BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers
12 Oct 21
Press Releases
PALO ALTO, Calif., Oct. 12, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, is announcing meaningful progress in its
Helsinn Group and BridgeBio Pharma's Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
29 Sep 21
Press Releases
Helsinn Group and BridgeBio Pharma's Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma - Health Canada Issues Conditional
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
15 Sep 21
Press Releases
PALO ALTO, Calif., Sept. 15, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
8 Sep 21
Press Releases
PALO ALTO, Calif., Sept. 8, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with